Skip to main content
. 2009 Jan;126(1):140–146. doi: 10.1111/j.1365-2567.2008.02887.x

Table 1.

Patient characteristics

Age (years) Present disease manifestations DMARD Pred. (mg/day) Anti-dsDNA (U/ml) SLAM score
Active SLE patients
391 Nephritis, arthritis None 5 68 8
26 Skin, haematological None 6·25 251 14
56 Arthritis AZA 10 ND 13
34 Nephritis, arthritis Chlorambucil 15 139 9
43 Nephritis, skin None 5 > 400 26
52 Nephritis None 10 314 8
64 Haematological None 5 ND 12
19 Nephritis AZA 20 ND 16
29 Nephritis, lymphadenopathy None 15 > 400 25
231 Nephritis, APS None 0 65 9
47 Skin, haematological, fever, nephritis 302 > 400 16
36 Arthritis, mental depression AZA ND 56 12
371 Nephritis MMF 8·75 52 9
45 Nephritis None 7·5 15 10
44 Haematological, hair loss, musculoskeletal AZA, AM 5 Neg 15
39 8·1 104 12
Inactive SLE patients
38 Inactive AZA, AM 2·5 Neg 1
59 Inactive None 6 Neg 2
69 Inactive AZA 4 Neg 4
39 Inactive AM2 0 Neg 4
35 Inactive None 0 110 6
80 Inactive None 0 Neg 4
58 Inactive None 0 ND 4
44 Inactive None 0 Neg 1
391 Inactive MMF 25 24 6
231 Inactive None 20 28 6
371 Inactive MMF 10 ND 5
47 6 Neg 4

Medians shown below columns in bold types.

AM, antimalarials; APS, antiphospholipid syndrome; AZA, azathioprine; DMARD, disease modifying anti-rheumatic drug; MMF, mycophenolate mofetil; ND, not determined; Pred., prednisolone; SLAM, systemic lupus erythematosus activity measurement; SLE, systemic lupus erythematosus.

1

Patients analysed during active and inactive SLE.

2

Recent onset.